London, United Kingdom--(Newsfile Corp. - November 21, 2025) - Edison issues report on Mendus (OMX: IMMU).
We have updated our investment view on Mendus following its expanded strategy for vididencel to chronic myeloid leukaemia (CML) and a broader acute myeloid leukaemia (AML) population, including chemo-eligible and chemo-ineligible patients, regardless of their measurable residual disease (MRD) status. In our view, this is a bold strategic pivot for a programme nearing Phase III readiness, but one that aligns with shifting treatment paradigms in AML and the growing clinical emphasis on achieving treatment-free remission (TFR) in CML. The broader positioning could strengthen partnering prospects, and we note that the recent SEK52.5m equity raise ameliorates any near-term capital-related risks stemming from the previously short cash runway. With clinical preparations underway, we have pushed our expected licensing timeline to early 2027 (previously Q126). Our valuation adjusts to SEK1.87bn, with the per-share valuation shifting to SEK29.8, due to the higher share count following the raise.
Click here to read the full report.
All reports published by Edison are available to download free of charge from its website.
www.edisongroup.com
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
enquiries@edisongroup.com
+44 (0)20 3077 5700
Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275439
SOURCE: Edison Group
